Advancing treatments for rare diseases Together

Update on clinical development of Rimeporide in Duchenne presented at the 21st International Congress of the World Muscle Society

05Oct

EspeRare is presenting its latest update on the clinical development of Rimeporide in Duchenne Muscular Dystrophy, "Translational Development of Rimeporide, a Sodium-Hydrogen Exchanger (NHE-1) Inhibitor, for Patients with Duchenne Muscular Dystrophy", at the 21st International Congress of the World Muscle Society in Grenada (Spain), October 4th to 8th.

rimeporide_esperare_WMS2016Click on picture to view

For more information on the WMS 2016 congress click here